T he role of angiostatin as an antiangiogenic and an antineoplastic agent has recently attracted much attention. [1] [2] [3] Angiostatin is a proteolytic product of plasminogen and matrix metalloproteinases (MMPs) and antagonizes the trophic effects of several growth factors, including vascular endothelial growth factor (VEGF). 2 In addition to its role as an angiogenic factor, VEGF is also an endothelium-dependent vasodilator. 4 Interestingly, both of these actions require ·NO. 4 Evidence for ·NO in collateral growth comes from the severely compromised responses found in studies involving both endothelial nitric oxide synthase (eNOS)-knockout mice and pharmacological and naturally occurring endogenous inhibitors of eNOS. [5] [6] [7] [8] With a growing list of angiogenic and physiological mechanisms centering on ·NO, we hypothesized that angiostatin inhibits endothelial-dependent vasodilation. This hypothesis is based on observations that (1) geldanamycin and radicicol, antineoplastic agents that inhibit heat-shock protein (hsp) 90, both attenuate ·NO-dependent signaling by uncoupling eNOS activity 9 -12 ; (2) endostatin inhibits eNOS by increasing dephosphorylation at S1177 13, 14 ; (3) angiostatin inhibits coronary angiogenesis to increase myocardial ischemia 15, 16 ; and (4) hsp90 enhances ·NO production from neuronal NOS. 17 These reports suggest that hsp90 may modulate which radical species is generated when eNOS is activated.
Methods

General
Animal care and treatment were conducted in accordance with the institutional guidelines of the Medical College of Wisconsin. Male Sprague-Dawley rats (220 to 300 g, Harlan, Indianapolis, Ind) were anesthetized with sodium pentobarbital (50 mg/kg IP). The heart and aorta were removed and placed in physiological saline solution at 4°C. Aortas (3 per test group; 12 per experiment) were cleaned of fat and adventitial tissue and cut into 4 pieces (5 to 8 mm long).
Angiostatin was synthesized from plasminogen 3, 18 and characterized by Western analysis. Digestion of plasminogen with MMP2ϩMMP9 yielded three products with molecular weights of 48, 38, and 32 kDa. 18, 19 This reaction mixture (Ϸ120 nmol/L from standards on the blot) inhibited VEGF-induced (10 ng/mL) endothelial proliferation and tube formation. Purified angiostatin (No. 176700, Calbiochem) yielded similar results.
Measurements of Vasodilation
Arterioles (53 to 168 m) were dissected from the interventricular septum, cannulated with glass micropipettes (tip diameter Ϸ30 m), and connected to 2 reservoirs filled with physiological saline solution. 20 Arterioles were stimulated with acetylcholine (ACh), VEGF, and papaverineϮangiostatin, and diameters were recorded by videomicroscopy. 20 To determine if O 2 ·Ϫ impaired endotheliumdependent vasodilation, arterioles were treated with polyethylene glycolated-superoxide dismutase (PEG-SOD) for 20 minutes (200 U/mL) before angiostatin.
Immunoprecipitation of eNOS and Western Analysis
The effects of angiostatin on hsp90 -eNOS interactions were determined on native endothelial cell on rat aortas and cultured bovine aortic endothelial cells (BAECs). Aortas were treated with buffer (Ϫ) or with 120 nmol/L angiostatin (ϩ) for 20 minutes, incubated with buffer (Ϫ) or 5 mol/L A23187 (ϩ) for 5 minutes, removed, flash-frozen in N 2 (l), pulverized, and homogenized by hand in modified radioimmunoprecipitation buffer. 11 Vascular debris was removed and aliquots (1000 g) were precleared. eNOS was immunoprecipitated (H32, BioMol); coprecipitated proteins separated by SDS-PAGE; and eNOS and hsp90 immunoblotted with primary antibodies 9D10 (Zymed) and H38220 (Transduction Labs) and enhanced chemiluminescence reagents (Amersham), as described. 11 To determine effects of angiostatin on A23187-stimulated eNOS-hsp90 interactions and phospho-eNOS (S1177) (p-eNOS), BAEC cultures were serum-starved (0.5% FBS) in RPMI-1640 (4 to 6 hours) and incubated with buffer (Ϫ) or with 120 nmol/L angiostatin (ϩ) (37°C, 15 minutes). The cultures were washed and stimulated with 5 mol/L A23187 (ϩ) for 10 minutes in Hank's balanced salt solution containing L-arginine (10 mol/L) and angiostatin. Cultures were lysed and eNOS immunoprecipitated as described. 11 The proteins were separated by SDS-PAGE and immunoblotted for p-eNOS (9571, Cell Signaling), eNOS, and hsp90 as above. 11 
Data Analysis
Data were analyzed by the Student's t test (unpaired, 2 tailed, with Welch's correction) or by ANOVA with Fisher's post-hoc test to determine significance among test groups, with the use of Statview 4.51 for MacIntosh computers. A probability value Ͻ0.05 was accepted as being statistically significant.
Results
Angiostatin induced a modest vasodilation (3% to 6%) under basal conditions. When the pressurized microvessels were stimulated, however, angiostatin impaired ACh-and VEGFbut not papaverine-induced vasodilation (Figure 1, A, B , and C, respectively). L-NAME inhibited vasodilation to ACh and VEGF to the same extent as angiostatin (data not shown).
PEG-SOD improved vasodilation when angiostatin-treated arterioles were stimulated with ACh and VEGF but not papaverine (Figure 1) . The inhibitory effects of angiostatin were reversible, in that washing the microvessels restored vasodilation.
Angiostatin decreased hsp90 interactions with eNOS in native endothelial cells on rat aortas by 71.8Ϯ9.0% of the levels in control aortas ( Figure 2A Because p-eNOS levels directly correlate with increased electron flow, 21 and hsp90 association with eNOS enhances ·NO formation, 9,11 these data indicate angiostatin alters mech- anisms of eNOS activation such that an increase in electron flow occurs under less than optimal conditions. Such changes in radical species generation are consistent with the idea that angiostatin decreases ·NO bioactivity in pressurized arterioles by uncoupling eNOS activity. On the basis that ·NO is required for endothelial proliferation and vasodilation, our findings provide new insight into why angiostatin is not only antiangiogenic but also able to impair endothelium-dependent vasodilation.
This mechanism for angiostatin complements the mechanism for endostatin, which increases dephosphorylation of eNOS at S1177 without inhibiting Akt activity. 14 As angiostatin uncouples eNOS activity and endostatin decreases p-eNOS levels, 14 it is easy to see how a shift in the balance of angiogenic and antiangiogenic factors not only inhibits collateral growth 15 but also impairs endothelial-dependent vasodilation.
This change in association between eNOS and hsp90 may also contribute to endothelial dysfunction in diabetes, hypertension, and hyperlipidemia, in which increased MMPs were detected. [22] [23] [24] Logically, an increase in vascular MMP activity could enhance plasminogen degradation to angiostatin, which, on the basis of the findings here, would uncouple eNOS activity to impair vasodilation.
In summary, angiostatin, an endogenous vasostatic molecule, alters hsp90 interactions with eNOS to impair vasodilation. Whenever the endothelium is stimulated in the presence of angiostatin, less hsp90 associates with eNOS. This shifts ·NO and O 2 ·Ϫ generation by eNOS from ·NO toward O 2 ·Ϫ . Our data indicate angiostatin acts as a negative regulator of endothelial-dependent vasodilation by uncoupling eNOS activity.
